Increased levels of KL-6 in COVID-19 patients were associated with a more severe lung disease.<h4>Discussion and conclusion</h4>Our results suggest that KL-6 could be a good biomarker to assess ILD severity in COVID-19 infection. Here, MUC1 is linked to lung disorder.